October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
In today's rapidly evolving field of biomanufacturing, traditional methods often fall short of the rigorous demands for real-time data and consistent product quality. Laser Force Cytology (LFC) has emerged as an innovative, label-free technology that offers a transformative approach to
The global brain-computer interface (BCI) market is expected to grow from USD $2.1 million in 2022 to USD $9.4 million by 2032, with a growth rate of 16.7% from 2023 to 2032. This exciting area of research and development can create a direct communication link between the human brain and devices
Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment
Novo Nordisk recently announced its intention to seek regulatory approval for the use of semaglutide, the active ingredient in its profitable weight loss drug, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This decision came after a Phase 3 clinical trial yielded
The collaboration between ViaNautis Bio (ViaNautis) and Eli Lilly and Company (Lilly) marks a significant advancement in the field of genetic medicine. This partnership aims to leverage ViaNautis' cutting-edge polyNaut technology to develop precision genetic medicines that can deliver genetic
The Global Plasma Protein Therapeutics Market is on a significant growth trajectory, projected to reach approximately USD 40 billion by 2030. This expansion is driven by the indispensable role that plasma protein therapies play in treating a wide array of medical conditions, such as hemophilia,
Sterling Pharma Solutions is significantly expanding its GMP antibody-drug conjugate (ADC) manufacturing capacity with a £10 million investment aimed at doubling the current capacity at its Deeside, UK site. This expansion involves commissioning a new 2,300-square-foot suite, which includes a
In a pioneering move to advance cancer treatment, Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration aimed at developing a next-generation antibody-drug conjugate (ADC) platform. This partnership promises to leverage nCage's TRAP cage platform, a novel drug delivery
Biond Biologics Ltd., a private biopharmaceutical company, has entered into a partnership with Merck KGaA, Darmstadt, Germany, to support a Phase 1 clinical trial aimed at treating patients with unresectable or metastatic solid tumors. This clinical trial, designated as BND-35-001 (NCT06274437),
